<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561779</url>
  </required_header>
  <id_info>
    <org_study_id>YY_YYD302_003</org_study_id>
    <nct_id>NCT03561779</nct_id>
  </id_info>
  <brief_title>Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Study to Evaluated the Safety and Efficacy of Intraarticular Hyalurinic Acid(YYD302) for Osteoarthritis of the Knee After 12 Weeks of Treatment and Retreatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, active-controlled, multi-center, phase 3 study to
      evaluate the safety and efficacy of intraarticular hyaluronic acid(YYD302) for osteoarthritis
      of the knee after 12 weeks of treatment and retreatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First Injection: A multicenter, active-controlled, randomized, evaluator and subject
      bllinded, parallel, phase 3 study Re-Injection: A multicenter, active-controlled, randomized,
      parallel
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The Subjects are injected investigational Product (YYD302 or Synovian Inj.)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of the Weight-bearing pain(100mm-VAS) on 12 weeks after first injection in comparison with baseline</measure>
    <time_frame>Change of the week 12 from baseline</time_frame>
    <description>Weight-bearing pain(100mm-VAS) assessed by the subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the Weight-bearing pain(100mm-VAS) on 2, 4 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4 from baseline</time_frame>
    <description>Weight-bearing pain(100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the KOOS scales on the 2, 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>KOOS scales assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the rest pain(100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Rest pain(100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the Motion pain (100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Motion pain(100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Patient global assessment (100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Patient global assessment (100mm-VAS) assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the swelling in the knee joint from baseline to 2, 4, 12 weeks after administration</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Sweeling assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the tenderness on pressure in the knee joint from baseline to 2, 4, 12 weeks after administration</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Tenderness on pressure assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the Range Of Motion(ROM) in the knee joint on 2, 4, 12 weeks after administration with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Range of motion assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of the Weight-bearing pain on 12 weeks in comparison with baseline</measure>
    <time_frame>Change of the week 12 from baseline</time_frame>
    <description>Responder rate of the Weight-bearing pain assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of the OMERACT-OARSI on 12 weeks in comparison with baseline</measure>
    <time_frame>Change of the week 12 from baseline</time_frame>
    <description>Responder rate of the OMERACT-OARSI assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication count and the total amount on each visit after injection</measure>
    <time_frame>Change of the each visit(2, 4, 12, 24, 36 weeks) after injection</time_frame>
    <description>Use of rescue medication count and the total amount assessed by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy of secondary outcome 1~11 after 12 weeks(36weeks) compared with the Re-injection(24weeks) in re-injection subjects</measure>
    <time_frame>Change of the week 12 (36 weeks) after Re-injection(24weeks)</time_frame>
    <description>Each outcome assessed by the investigator or subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy of secondary outcome 1~11 after baseline compared with 2, 4, 12, 24, 36 weeks in Re-injection subjects</measure>
    <time_frame>Change of the week 2, 4, 12, 24, 36 from baseline</time_frame>
    <description>Each outcome assessed by the investigator or subject</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>YYD302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YYD302 (2ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synovian Inj.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synovian Inj. (3ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD302 2ml</intervention_name>
    <description>YYD302 2ml</description>
    <arm_group_label>YYD302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator: Synovian Inj.</intervention_name>
    <description>Active comparator: Synovian Inj.</description>
    <arm_group_label>Synovian Inj.</arm_group_label>
    <other_name>Synovian Inj.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [Visit 1, 2 Inclusion Criteria]

          1. Males or Females 40 years and older

          2. According to the clinical diagnosis standard of the American College of Rheumatology
             (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to
             over 3 conditions of followings.

        1) Over 50 years of age 2) Less than 30 minutes of morning stiffness 3) Crepitus on active
        motion 4) 4 bony tenderness 5) Bony enlargement 6) Nopalpable warmth of synvium 3. Within 6
        months from screening visit, someone who diagnosed with Kellgren &amp; Lawrence Grade I~III by
        the radioactive examination.

        4. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the
        single or both sides of the osteoarthritis is over 40mm 5. Patient (No-responder) who has
        experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past.

        6. Patient who can walk by themselves without helper like cane or walker etc. (If the
        patient who has used helper routinely from previous 6 months, evaluating the patient
        including the helper is possible. In this case, patient needs to use same helper
        continuously by end of the clinical trial test.) 7. Patient who agrees to participate in
        this clinical trial by themselves.

        [Visit 6, 7 Inclusion criteria] 1. According to the clinical diagnosis standard of the
        American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of
        osteoarthritis, who corresponds to over 3 conditions of followings.

          1. Over 50 years of age

          2. Less than 30 minutes of morning stiffness

          3. Crepitus on active motion

          4. 4 bony tenderness

          5. Bony enlargement

          6. Nopalpable warmth of synvium 2. At Re-screening visit, someone who diagnosed with
             Kellgren &amp; Lawrence Grade I~III by the radioactive examination.

        3. Patient who can walk by themselves without helper like cane or walker etc. (If the
        patient who has used helper routinely from previous 6 months, evaluating the patient
        including the helper is possible. In this case, patient needs to use same helper
        continuously by end of the clinical trial test.) 4. Patient who are confirmed for Responder
        by efficacy at visit 5.

        Exclusion Criteria:

          1. Someone who has BMI≥32kg/m² at the screening visit.

          2. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can
             have an effect on pain sense over 3 months habitually.

          3. Patient who has been administrated gastrointestinal drug(for example H₂-blockers,
             misoprostol or proton pump inhibitors) regularly, who can't stop injecting for
             clinical study period.

          4. Patient has attended abnormal values from screening test(2 times excess at upper limit
             of the normal values at ALT, AST, BUN, Serum Creatinine).

          5. Patient who has rheumarthritis or other inflammatory metabolic arthritis.

          6. Patients having serious gastrointestinal, liver, renal, heart disease.

          7. When the inflammatory disease is occurred on joint area to patient like septic
             arthritis.

          8. Patients having skin ailment at the injecting site of the joint region.

          9. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis
             or systemic disease.

         10. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc
             herniation.

         11. Poly-articular patients who have suffered seriously by osteoarthritis at other parts
             affect judge of the knee joint pain.

         12. Patients who diagnosed clear interval disappearance at the knee joint by X-ray.

         13. Patients who were administrated below drugs before baseline visit. 1) Patients who
             were injected HA at the target knee joint or other parts of knee joint in recent 9
             months.

        2) Patients who were injected steroids into the intra-articular knee joint in recent 3
        months 3) Patients who were administrated steroids systemically by the oral medication
        (But, except inhalation) 4) Patients who were administerated Osteoarthritis nutrition such
        as glucosamine/chondroichin sulfate or physical therapy or herbal remedy(acupuncture,
        yellowish swelling, moxa cautery) for the purpose of pain relief in recent 2 weeks 5)
        Patients who have administerated steroid/No-steriod NSAIDs or other pain relief drugs
        (patch or other external medicine) in recents 2 weeks except Acetaminophen or below
        300mg/day of Asprin 14. Patients who have joint effusion trouble were judged as a positive
        by tests like Patella tap test.

        15. Patients who have target knee joint gotten surgical operation history including
        Arthroscopy within past one year (In case of having other side of knee joint or hip joint
        gotten surgical operation history, excepting the patients if there is possibility which can
        influence the target knee joint's appraisal.

        16. Patients who have an operation history about target knee joint. 17. Patients who do the
        height weight aerobic exercise or anaerobic exercise. 18. Patients who need to be
        administrated anticoagulant agent together(But, except 300mg daily dose aspirin) 19.
        Patients who have hypersensitivity history about Investigational Product. 20. In the midst
        of women in their childbearing years, patients who disagree to do * contraception by
        medically permitted method for 12 weeks from administrating investigational product.

          -  The contraception by medically permitted method: Condom, In case of using injection or
             insertion, In case of installing a intrauterine contraception device etc.

             21. Pregnant and lactating women 22. Patients who were injected other investigational
             product over a time within 30 days before participated in this clinical trail.

             23. Besides that, the patients who have difficulty to be participated in this clinical
             trial continuously by Principle Investigator (PI)'s decision.

          -  Exclusion criteria for Re-injection is except for 13-1) Re-injection date is followed
             by visit 7.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Won Ha, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Department of Internal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Kyung Kwon</last_name>
    <phone>+82-2-6207-6114</phone>
    <email>mkkwon@yypharm.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji-Yeon Won</last_name>
    <phone>+82-2-6207-6114</phone>
    <email>jywon@yypharm.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chul-Won Ha, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>June 17, 2018</last_update_submitted>
  <last_update_submitted_qc>June 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

